This activity is intended for medical oncologists, gynecological oncologists, gynecologists, pathologists, and other healthcare professionals who diagnose, treat, and manage cervical cancer.
The goal of this activity is to provide clinicians with the most recent clinical advances in cervical cancer and the application of current evidence to clinical practice to improve patient outcomes and quality of life.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and AXIS Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Robert A. Burger, MD, FACOG, FACS, reported a financial interest/relationship or affiliation in the form of: consulting fee, Amgen, Inc., Boehringer Ingelheim, Genentech, Inc.
Krishnansu S. Tewari, MD, FACOG, FACS, reported a financial interest/relationship or affiliation in the form of: advisory board, Caris Life Sciences, Inc., ADVAXIS, and Genentech, Inc.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS; Diedrea White, BA; and Deborah Middleton, MS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Safeguards Against Commercial Bias
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
1. Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
There is no fee for this educational activity.
Jointly provided by
This activity is supported by an independent educational grant from Genentech.